Rethinking the Appraisal and Approval of Drugs for Fracture Prevention
Sign Up to like & getrecommendations! Published in 2017 at "Frontiers in Pharmacology"
DOI: 10.3389/fphar.2017.00265
Abstract: Background: In January 2014, the EMA's Pharmacovigilance Risk Assessment Committee recommended that strontium ranelate no longer be used for osteoporosis. However, EMA's Committee for Medicinal Products for Human Use decided to restrict its use rather… read more here.
Keywords: fracture prevention; drugs fracture; harm benefit; rethinking appraisal ... See more keywords